Citation Impact
Citing Papers
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Therapeutic efficacy of Artemether/Lumefantrine (Coartem®) against Plasmodium falciparum in Kersa, South West Ethiopia
2010 Standout
Nuclear receptor PXR, transcriptional circuits and metabolic relevance
2011
Liquid chromatography/tandem mass spectrometric bioanalysis using normal‐phase columns with aqueous/organic mobile phases – a novel approach of eliminating evaporation and reconstitution steps in 96‐well SPE
2002
Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life
2013
Gut microbiome and health: mechanistic insights
2022 Standout
Hydrophilic interaction chromatography
2006 Standout
Emtricitabine
2005
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
2009
A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response
2016 StandoutNobel
A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase
2018 StandoutNobel
Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients
2019
Drug Interactions Between Antiretroviral Drugs and Comedicated Agents
2003
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether‐lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjects
2002
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
2009
The blood-brain barrier: Bottleneck in brain drug development
2004 Standout
Stem cell-derived polarized hepatocytes
2020 StandoutNobel
Assessing the Efficacy of Highly Active Antiretroviral Therapy in the Brain
2003
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis
2005 Standout
Triptans and CNS Side-Effects
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz
2001
Rifampin Combination Therapy for Nonmycobacterial Infections
2010
Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety
2010 Standout
Sexually Transmitted Diseases Treatment Guidelines, 2010
2011 Standout
Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?
2019 Standout
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
2016
Neuraminidase inhibitors for preventing and treating influenza in adults and children
2014
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
2010 Standout
Prosthetic Joint Infection
2014 Standout
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
2011
Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials
2002
Works of Gregory E. Chittick being referenced
Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects
2001
The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)
1997
Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial
2017
Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers
2007
Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men
1999
Pharmacokinetic Interaction of Abacavir (1592U89) and Ethanol in Human Immunodeficiency Virus-Infected Adults
2000
Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males
2001
737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS
2011
Pharmacokinetics and Safety of Single Oral Doses of Emtricitabine in Human Immunodeficiency Virus-Infected Children
2003
Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection
1999
Pharmacokinetics of [ 14 C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study
1999
Pharmacokinetics of Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Saquinavir Mesylate Administered Alone or in Combination at Steady State
2006
Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults
1999